A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)

May 25, 2021
https://clinicaltrials.gov/ct2/show/NCT04542499
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson's Disease, Motor Fluctuations, Movement Disorders, Parkinsonian Disorders
Accepting Participants